PROGRAMMABLE NUCLEASES FOR GENOME EDITING
=========================================

Genome editing is a method of modifying genome sequences in cells and whole organisms via custom-designed programmable nucleases ([@b20-molce-38-6-475]), which cleave chromosomal DNA in a targeted manner, producing site-specific DNA double-strand breaks (DSBs). These DSBs are efficiently repaired in cells by endogenous DNA repair systems known as homologous recombination (HR) and non-homologous end joining (NHEJ), often causing site-specific genome modifications. This technique is now widely used in research, medicine, and biotechnology, a phenomenon that is highlighted by the choice of genome editing as the 2011 Method of the Year and one of the 2015 Methods to Watch by Nature Methods and as a Breakthrough of the Year runner-up by Science in 2013. For example, gene knockout using engineered nucleases enables identification and validation of drug-able target genes. Gene correction in stem and somatic cells can lead to gene therapy for the treatment of various genetic and non-genetic diseases.

Three different classes of programmable nucleases have been developed: zinc finger nucleases (ZFNs) ([@b2-molce-38-6-475]; [@b22-molce-38-6-475]; [@b23-molce-38-6-475]; [@b51-molce-38-6-475]), transcription activator-like effector nucleases (TALENs) ([@b26-molce-38-6-475]; [@b28-molce-38-6-475], [@b38-molce-38-6-475]), and RNA-guided endonucleases (RGENs) ([@b6-molce-38-6-475]; [@b7-molce-38-6-475]; [@b9-molce-38-6-475]; [@b37-molce-38-6-475]) repurposed from the type II CRISPR system, an adaptive immune response in bacteria and archea.

ZFNs and TALENs consist of a common nuclease domain derived from FokI, a type IIS restriction enzyme, and distinct DNA-binding domains: ZFNs use zinc fingers ([@b21-molce-38-6-475]), whereas TALENs employ TAL effectors derived from Xanthomonas, a plant pathogen ([@b4-molce-38-6-475]; [@b39-molce-38-6-475]). These DNA-binding domains can be engineered to target user-defined DNA sequences. Because the FokI nuclease domain must dimerize to cleave DNA ([@b3-molce-38-6-475]), these FokI-based nucleases function as pairs, contributing to their high specificities. Typically, a ZFN pair recognizes an 18-to 36-bp DNA sequence, and a TALEN pair recognizes a 30- to 40-bp DNA sequence, surpassing the complexity of the human genome (4E16 = 4.3 billion \> 3.2 billion, the size of the human genome). In practice, however, these nucleases can induce off-target mutations. Furthermore, many ZFNs, especially those made using publically-available zinc-finger resources, are cytotoxic ([@b22-molce-38-6-475]), which may arise from their off-target effects. Custom-made ZFNs, available from a commercial source, are more potent and specific but are expensive. ZFNs prefer guanine-rich target sequences, limiting targetable sites.

TALENs, the 2^nd^ generation of programmable nucleases, can be designed to target almost any DNA sequence, a critical advantage over ZFNs and RGENs. Unlike zinc fingers that recognize 3-bp sub-sites, TAL effector modules recognize single bases. Four different modules, each specific to one of the four bases, are used to make TALENs. TAL effector arrays often consist of up to 20 modules, making it time-consuming and labor-intensive to prepare plasmids that encode TALENs. In general, TALENs are not cytotoxic, but can induce off-target mutations ([@b40-molce-38-6-475]). Fortunately, TALEN off-target effects can be avoided by choosing unique target sequences that differ by at least 7 nucleotides from any other site in the genome ([@b26-molce-38-6-475]). A web-based resource ([www.talenlibrary.net](www.talenlibrary.net)) provides such unique sites in each human gene.

CRISPR/Cas-derived RGENs constitute yet another class of programmable nucleases. RGENs consist of a target-specific CRISPR RNA (crRNA), a target-independent trans-activating crRNA (tracrRNA), and Cas9, the protein component originated from Streptococcus pyogenes. Essential portions of crRNA and tracrRNA can be linked to form a single-chain guide RNA (sgRNA) ([@b18-molce-38-6-475]). Both crRNAs and sgRNAs function as guide RNAs (gRNAs) to direct Cas9 to target sites. The specificity of an RGEN is determined by both the gRNA, which hybridizes with a 20-bp target DNA sequence, and Cas9, which recognizes the 5′-NGG-3′ sequence known as the protospacer-adjacent motif (PAM). New RGENs with desired specificity are prepared by replacing *in vitro* transcribed gRNA or gRNA-encoding plasmids, making these 3^rd^ generation nucleases affordable and scalable. Unlike ZFNs and TALENs, however, RGENs function as monomers, initially raising concerns about their specificity. Indeed, RGENs can induce unwanted mutations at off-target sites that differ by up to several nucleotides from on-target sites ([@b8-molce-38-6-475]; [@b10-molce-38-6-475]; [@b13-molce-38-6-475]; [@b17-molce-38-6-475]). This means that there are thousands of potential off-target sites per RGEN in the human genome.

WHY DO NUCLEASE OFF-TARGET EFFECTS MATTER?
==========================================

Programmable nucleases can cut their target sites efficiently inducing site-specific DSBs in the genome, but can also create unwanted cleavages at off-target sites with high sequence homology to on-target sites, often inducing off-target mutations. Thus, both zinc finger proteins and TAL effector arrays can bind to homologous sites, leading to off-target DNA cleavages. RGEN off-target mutations are caused by both Cas9 and gRNAs. The optimal PAM sequence recognized by Cas9 derived from S. pyogenes is 5′-NGG-3′. However, Cas9 can cleave sites with a 5′-NAG-3′ or 5′-NGA-3′ PAM albeit less efficiently ([@b17-molce-38-6-475]). A few nucleotide mismatches between a 20-nt gRNA sequence and a target DNA sequence is also tolerated by an RGEN. Mismatches in the PAM-distal sequence at the 5′ terminus are tolerated better than are those in the 10-to 12-nt PAM-proximal sequence, often termed a seed region. Furthermore, RGENs can cleave off-target sites with a few extra or missing nucleotides that can produce a DNA or RNA bulge, respectively ([@b35-molce-38-6-475]).

Imprecise repair of on- and off-target DNA cleavages can give rise to gross chromosomal rearrangements such as deletions ([@b33-molce-38-6-475]), inversions ([@b34-molce-38-6-475]; [@b42-molce-38-6-475]), and translocations ([@b5-molce-38-6-475]; [@b8-molce-38-6-475]), in addition to local mutations. An example is a ZFN designed to target the C-C chemokine receptor 5 (*CCR5*) gene that encodes an essential co-receptor of human immunodeficiency virus (HIV) infection in helper T cells. A phase I/II clinical trial with this ZNF for the treatment of acquired immune deficiency syndrome (AIDS) has been completed in the US ([ClinicalTrials.gov](ClinicalTrials.gov) identifier: NCT00842634) ([@b49-molce-38-6-475]). This ZFN also cleaves a highly homologous site in the *CCR2* gene, leading to ∼15-kbp chromosomal deletions, duplications, and inversions of the intervening DNA segment in human cells ([@b33-molce-38-6-475]; [@b34-molce-38-6-475]). It is unknown whether the off-target mutation at the *CCR2* gene and the resulting unwanted chromosomal rearrangements would cause any side effects in AIDS patients. Chromosomal rearrangements are one of the hallmarks of cancer. Because unwanted chromosomal rearrangements may activate onco- genes, they must be monitored carefully and avoided as much as possible.

METHODS FOR DETECTING ON-TARGET AND OFF-TARGET MUTATIONS
========================================================

Various methods, which include Sanger sequencing, high-throughput sequencing, restriction fragment length polymorphism (RFLP) analysis, mismatch-sensitive enzymes, have been developed for detecting indels induced by erroneous NHEJ repair of DSBs. Sanger sequencing of DNA from individual clones is the gold standard for confirming nuclease-triggered mutations at on- or off-target sites, but this method is time-consuming and cost-inefficient when many samples need to be analyzed in parallel. High-throughput sequencing enables accurate measurements of indel frequencies at up to hundreds of on- and off-target sites at once. Although this method is highly sensitive, allowing detection of indels that are induced with frequencies that range from 0.01% to 1% (∼0.1% on average), care must be taken to discard false-positive sequence reads that result from PCR artifacts and to include a negative control (no nuclease expression) at each target site ([@b8-molce-38-6-475]). A web-based tool ([www.regenome.net](www.regenome.net)) is available for obtaining indel frequencies using targeted deep sequencing data. Single-molecule real-time (SMRT) sequencing is an alternative method for measuring on- and off-target mutation frequencies ([@b16-molce-38-6-475]).

Mismatch-sensitive nucleases, which include T7 endonuclease I (T7E1) ([@b22-molce-38-6-475]) and CEL-I enzyme (a.k.a. Surveyor nuclease) are widely used to measure indel frequencies in bulk populations of cells. These enzymes recognize and cleave heteroduplexes formed by hybridization of wild-type and mutant DNA sequences or of two different mutant DNA sequences. PCR amplicons treated with these enzymes are then subjected to agarose gel electrophoresis. The size and intensity of cleaved DNA bands provide accurate measurements of mutation frequencies. Although these enzymes can detect both indels and point mutations, T7E1 is more sensitive to indels than CEL-I enzyme ([@b53-molce-38-6-475]). Because programmable nucleases rarely produce point mutations ([@b27-molce-38-6-475]), T7E1 is preferred for detecting nuclease-induced mutations. In fact, under optimal conditions, T7E1 can detect indels that are induced at frequencies below 1% ([@b26-molce-38-6-475]).

In contrast to agarose gel electrophoresis, polyacrylamide gel electrophoresis (PAGE) can be used to separate heteroduplexed DNA from homoduplexed DNA by without the use of mismatch-sensitive nucleases ([@b56-molce-38-6-475]). However, accurate quantitation of mutation frequencies using this method is difficult because multiple DNA bands are obtained.

Programmable nucleases often induce homozygous biallelic mutations in a cell or an organism, leading to a complete gene disruption or knockout. These mutations cannot be detected by T7E1 or CEL-I, because heteroduplexes are not formed. RGENs can be used for RFLP analysis to distinguish homozygous biallelic mutants from wild-type sequences or monoallelic mutations ([@b29-molce-38-6-475]). Thus, RGENs cannot cleave indel sequences induced by themselves in cells. In fact, RFLP analysis using conventional restriction enzymes was one of the first methods for detecting mutations induced by programmable nucleases in cells ([@b51-molce-38-6-475]). However, unlike RGEN-RFLP, this method is limited by the availability of appropriate restriction sites in a target DNA site. Fluorescence PCR ([@b24-molce-38-6-475]) and DNA melting analysis ([@b41-molce-38-6-475]) can also be used for measuring genome editing activities of programmable nucleases, but these methods require special devices.

METHODS FOR MEASURING OFF-TARGET EFFECTS IN THE GENOME
======================================================

Several different methods have been used to identify nuclease off-target sites: bioinformatic prediction based on sequence homology, chromatin immunoprecipitation coupled with deep sequencing (ChIP-Seq), systematic evolution of ligands by exponential amplification (SELEX), integrase-deficient lentivirus (IDLV) capture in cells, *in vitro* selection using a DNA substrate library for nuclease-mediated DNA cleavage, and whole genome/exome sequencing ([Figs. 1A--1C](#f1-molce-38-6-475){ref-type="fig"}).

Cas9 and other programmable nucleases can induce off-target mutations at sites that differ from their on-target sites by several nucleotides. This means that more than 10,000 potential off-target sites identified based on sequence homology must be examined. A web-based computer program, CAS-OFFinder ([@b1-molce-38-6-475]), can be used to list all of these homologous sites, but measuring indel frequencies at these sites one by one is an almost impossible task. To profile genome-wide off-target effects of engineered nucleases in an unbiased manner, SELEX ([@b38-molce-38-6-475]) and ChIP-Seq ([@b32-molce-38-6-475]; [@b54-molce-38-6-475]) have been used. These methods rely on DNA binding *in vitro* and in cells, respectively, rather than DNA cleavage. Unfortunately, DNA binding and cleavage are often uncoupled. In fact, most off-target DNA-binding sites recognized by catalytically dead Cas9 (dCas9) are not cleaved at all by Cas9 in cells.

IDLV capture and *in vitro* selection are two different methods that examine nuclease cleavage sites rather than binding sites. IDLV capture relies on integration of IDLV DNA at off-target sites in cells ([@b15-molce-38-6-475]). Because the efficiency of IDLV capture at a given site is much lower than the mutation frequency at that site, many bona fide off-target sites cannot be captured by this method. *In vitro* selection uses nucleases to cleave a biased DNA substrate library that consists of \>10^12^ variants of a target DNA sequence and determines cleaved library members by deep sequencing ([@b43-molce-38-6-475]; [@b44-molce-38-6-475]). Although this is a powerful method of profiling nuclease specificity *in vitro*, most cleaved sequences do not exist in the genome. Furthermore, this approach cannot examine off-target cleavage at sequences that can hybridize with a DNA or RNA bulge.

These two methods are complementary but neither of them is comprehensive. [@b15-molce-38-6-475] and [@b43-molce-38-6-475] have applied IDLV capture and in vitro selection, respectively, to examine off-target effects of the same *CCR5*-targeting ZFN that has been under clinical investigation for the treatment of HIV infection. The two groups obtained almost entirely different sets of off-target sites: only the highly homologous *CCR2* off-target site was commonly identified, highlighting the limitation of the two approaches.

Whole genome/exome sequencing of clonal populations of human cells in which a gene of interest was modified using ZFNs ([@b55-molce-38-6-475]), TALENs ([@b48-molce-38-6-475]; [@b52-molce-38-6-475]), or RGENs ([@b8-molce-38-6-475]; [@b31-molce-38-6-475]) revealed remarkable specificities of these nucleases. Although these nucleases have detectable off-target effects in a bulk population of cells, off-target mutations are almost absent in the entire human exome or genome of an individual clone. This is because mutation frequencies at off-target sites are usually orders of magnitude smaller than those at on-target sites. Off-target mutations that occur at a frequency of 10% cannot be revealed by sequencing of DNA from just a few clones with a typical depth of 30X.

In the following two sections, we review recently improved methods for profiling genome-wide off-target sites of Cas9 nucleases and various approaches for reducing or avoiding their off-target effects. Some of these methods can also be applied to other programmable nucleases.

UNBIASED GENOME-WIDE PROFILING OF NUCLEASE CLEAVAGE SITES
=========================================================

Recently, four different methods have been reported for identifying potential off-target sites of RGENs in a bulk population of cells ([Figs. 1C--1F](#f1-molce-38-6-475){ref-type="fig"}). Genome-wide, unbiased identification of DSBs enabled by sequencing (GUIDE-seq) represents an improvement over IDLV capture ([@b50-molce-38-6-475]). Blunt-ended, double-stranded phophothiorate oligodeoxynucleotides (dsODNs) can be captured at on-target and off-target sites, when DSBs are repaired by NHEJ in cells. These dsODN integration sites are mapped in the genome by PCR amplification and deep sequencing. High-throughput genomic translocation sequencing (HTGTS) exploits translocations that are induced by erroneous ligation of on-target and off-target sites in cells ([@b12-molce-38-6-475]). HTGTS identifies off-target sites by using the on-target DSB as a 'bait' to catch 'prey' sequences that are trans-located to the on-target site. High-throughput sequencing is used to determine prey sequences that correspond to off-target sites.

Off-target DSBs can also be captured in fixed, permeable cells. Breaks labelling, enrichments on streptavidin and next-generation sequencing (BLESS) is performed by labelling DSBs present in fixed cells using biotinylated oligonucleotides, which are then enriched and subjected to deep sequencing ([@b11-molce-38-6-475]; [@b47-molce-38-6-475]). Because this method captures DSBs at a single moment, many bona fide off-target cleavage sites can be missed, resulting in poor sensitivity.

Cell-free genomic DNA can be used to profile nuclease off-target effects *in vitro*. Digested genome sequencing (Digenomeseq) is a method for identifying off-target sites using nuclease-digested genomic DNA (digenome) that is subjected to whole genome sequencing ([@b31-molce-38-6-475]). *In vitro* digestion of genomic DNA with Cas9 yields sequence reads with the same 5′ ends at cleavage sites, which can be computationally identified using whole genome sequence data.

A key difference between these methods is whether genomic DNA is cleaved in cells or *in vitro*. Both HTGTS and GUIDE-seq rely on DNA cleavage and repair in cells. In contrast, Digenome-seq is based on digestion of cell-free genomic DNA. In BLESS, DNA is cleaved by a nuclease of interest in cells, but the resulting DSBs are captured *in vitro*. Note that DSBs are spontaneously generated in cells even in the absence of an engineered nuclease. These naturally-occurring nuclease-independent DSBs are captured by HTGTS, GUIDE-seq, and BLESS. Furthermore, these methods are susceptible to PCR artifacts that arise from amplification of sequences around DSB sites. These false-positive signals must be filtered out by searching for sequences around the captured sites that are homologous to the on-target site. Up to 95% of captured sites are discarded in this filtering step. Digenome-seq is not limited by Cas9-independent DSBs produced in cells or *in vitro* or by PCR artifacts, because these randomly-occurring DSBs are unlikely to produce the same 5′ ends and because PCR is not used to prepare Cas9-digested genomic DNA.

It is unknown to what extent programmable nucleases are limited by chromatin. Because HTGTS, GUIDE-seq, and BLESS profile nuclease cleavage sites in cells, off-target sites captured in one cell type could be different from those in other cell types, owing to differential chromatin accessibility in each cell type. Digenome-seq functions independently of the cell type, because naked, chromatin-free genomic DNA is used.

DSB repair by NHEJ in cells often result in deletions of sequences of up to hundreds of base pairs in length at cleavage sites. As a result, neither HTGTS nor GUIDE-seq can pinpoint off-target sites: One must search for potential off-target sites based on the sequence homology around captured sites. Both BLESS and Digenome-seq do not depend on NHEJ and can pinpoint cleavage sites at single-nucleotide resolution.

To determine which method is most sensitive and comprehensive, one needs to test the same nucleases using each of these methods. Only one sgRNA, specific to the VEGF-A site, has been tested by HTGTS ([@b12-molce-38-6-475]), GUIDE-seq ([@b50-molce-38-6-475]), and Digenome-seq ([@b31-molce-38-6-475]) thus far. Each of these methods revealed a different set of potential off-target sites, suggesting that no method is comprehensive. However, most of these candidate sites were invalidated by targeted deep sequencing. Importantly, these three methods commonly identified a total of 7 off-target sites in addition to the on-target site in the human genome. Notably, Digenome-seq identified one additional bona fide off-target site, with an indel frequency of 0.065%, which was validated using deep sequencing.

HOW TO REDUCE OFF-TARGET MUTATIONS CAUSED BY CRISPR-CAS9 NUCLEASES
==================================================================

First, the choice of unique target sequences, which differ from any other sites in the genome by at least 2 or 3 nucleotides in a 20-nt sequence, is important for avoiding off-target effects ([@b8-molce-38-6-475]). RGENs discriminate efficiently against potential off-target sites with mismatches in the PAM sequence and the seed region upstream of the PAM sequence. A web-based computer algorithm is available (<http://www.rgenome.net/casoffinder>), which searches for potential off-target sites and unique target sequences in the genomes of humans and 20 other organisms of research interest ([Table 1](#t1-molce-38-6-475){ref-type="table"}). Alternative web-based tools are also available: CRISPR Design (<http://crispr.mit.edu>) introduces a scoring system for choosing sgRNAs with minimum off-target ites. ChopChop (<http://chopchop.re.fas.harvard.edu>) provides a user-friendly sgRNA designer program. Second, the use of four different forms of modified sgRNAs can reduce off-target mutations by orders of magnitude without sacrificing mutation efficiencies at on-target sites ([Fig. 2A](#f2-molce-38-6-475){ref-type="fig"}). First, sgRNAs with two extra, target independent guanine nucleotides at the 5′ terminus are much more specific than conventional sgRNAs at least in human cells ([@b8-molce-38-6-475]). The addition of two extra guanine nucleotides also allows sgRNAs that begin with nucleotides other than guanine to be made, which is required for transcription under the control of U6 promoter in cells or the T7 promoter *in vitro*. It is unknown how the two additional guanine nucleotides make sgRNAs more specific. Second, truncated sgRNAs (tru-sgRNAs) with 17-nt, rather than 20-nt, of complementarity enhance the specificity of RNA-guided genome editing ([@b14-molce-38-6-475]). Tru-sgRNAs are more sensitive to mismatches, owing to their reduced binding energy at the sgRNA-DNA interface. It is still important to choose unique 17-nt target sites to minimize off-target effects. Unfortunately, 17-nt sites that differ from any other sites in the human genome by at least 2 or 3 nucleotides are much rarer than such 20-nt full-length sites.

Third, paired nickases can generate two single-strand breaks or nicks on different DNA strands, producing a composite DSB and doubling the specificity of genome editing ([Fig. 2B](#f2-molce-38-6-475){ref-type="fig"}) ([@b8-molce-38-6-475]; [@b25-molce-38-6-475]; [@b36-molce-38-6-475]; [@b46-molce-38-6-475]). Both ZFNs and Cas9 can be converted to nickases by inactivating one active site. Cas9 has two active sites, each cleaving either the Watson or Crick strand. Among the two nickase forms, D10A Cas9 appears more efficient and robust than H840A Cas9. One caveat to this approach is that two active sgRNAs are required to make a functional Cas9 nickase pair. Furthermore, target sequences must contain two PAM sequences, limiting the choice of targetable sites.

Fourth, the use of recombinant Cas9 protein \[commercially available from ToolGen ([www.toolgen.com](www.toolgen.com))\], rather than the Cas9-encoding plasmid, further reduces off-target mutations ([Fig. 2C](#f2-molce-38-6-475){ref-type="fig"}) ([@b30-molce-38-6-475]). Cas9-sgRNA ribonucleoprotein (RNP) complexes induce mutations at target sites almost immediately after delivery into cells and are degraded rapidly by endogenous proteases, reducing off-target effects without compromising on-target mutation frequencies. In fact, RGEN RNP delivery is more efficient and less stressful than plasmid transfection in human primary cells and pluripotent stem cells, in which the cyclic GMP-AMP synthase (cGAS) signalling pathway is active. In most cancer cells, in which the cGAS signalling pathway is inactive, plasmid transfection and RNP delivery produce comparable results. Furthermore, RGEN RNP delivery avoids the possibility of unwanted integration of plasmid fragments. RGEN RNPs can be delivered into cells via electroporation ([@b30-molce-38-6-475]) or lipofection ([@b57-molce-38-6-475]) or protein transdction ([@b45-molce-38-6-475]).

CONCLUSION
==========

Since we and others have reported RNA-guided genome editing in human cells in January, 2013 ([@b6-molce-38-6-475]; [@b9-molce-38-6-475]; [@b19-molce-38-6-475]; [@b37-molce-38-6-475]), the CRISPR-Cas9 system has been widely used in many labs all around the world to modify genomes in various organisms and cells. Although Cas9 nucleases have off-target effects, whole genome/exome sequencing of gene-modified clones shows that these nucleases are highly specific. Recent methods such as Digenome-seq and GUIDE-seq that profile genome-wide off-target sites in a bulk population of cells reveal a broad spectrum of sgRNA specificities. Certain sgRNAs are remarkably specific, resulting in no measurable off-target mutations, whereas others are promiscuous. To find rules that govern sgRNA specificity, one needs to profile the off-target effects of as many sgRNAs as possible at the genome-wide level. Digenome-seq is appealing in this regard, because it can be multiplexed without increasing the sequencing depth. Hundreds of sgRNAs can be tested in a single assay.

Genome-wide off-target profiling methods yield a list of potential off-target sites that are cleaved under certain conditions. Bona fide off-target sites must be validated by targeted deep sequencing. Unfortunately, validation of off-target effects is limited by intrinsic errors of sequencing platforms, which are in the range of 1% to 0.01% (0.1% on average). A more sensitive method is needed to confirm that certain sgRNAs do not induce off-target mutations with indel frequencies below 0.01% in the entire genome. Highly specific and efficient nucleases will enable applications in somatic gene and cell therapy and possibly in human germline genome editing to prevent the transmission of fatal genetic mutations.
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![Overview of methods for measuring off-target effects in the genome. (A) Chromatin immunoprecipitation coupled with deep sequencing (ChIP-Seq). (B) Systemic evolution of ligands by exponential amplification (SELEX). (C) Integrase-deficient lentivirus (IDLV) capture or genome-wide, unbiased identification of DSBs enabled by sequencing (GUIDE-seq). (D) High-throughput genomic translocation sequencing (HTGTS). (E) Breaks labelling, enrichments on streptavidin and next-generation sequencing (BLESS). (F) *In vitro* nuclease-digested genome sequencing (Digenome-seq). Ab, antibody, dCas9, catalytically-dead Cas9; DSB, double-strand break; ODN, oligodeoxynucleotide; sgRNA, small-guide RNA; WGS, whole-genome sequencing; WT, wild type.](molce-38-6-475f1){#f1-molce-38-6-475}

![Schematic strategies for reducing off-target mutations. (A) Four different forms of sgRNAs. sgRNAs with two extra guanines (ggX~20~) or truncated sgRNAs (gX~17~) enhance the specificity of RNA-guided genome editing, compared to conventional sgRNAs (gX~19~ or gX~20~). (B) Use of paired nickases to generate two single-strand breaks or nicks on different DNA strands. (C) Use of Cas9-sgRNA ribonucleoprotein (RNP) complexes, rather than the Cas9 and sgRNA-encoding plasmids to avoid continuous expression of Cas9 and sgRNA from plasmids.](molce-38-6-475f2){#f2-molce-38-6-475}

###### 

Web-based tools available for guide-RNA design

  Name                      Developer                                               Address
  ------------------------- ------------------------------------------------------- ----------------------------------------------------
  Cas-OFFinder              Jin-Soo Kim lab, Seoul National University              <http://www.rgenome.net/>
  CHOPCHOP                  George Church lab, Harvard University                   <https://chopchop.rc.fas.harvard.edu/>
  CRISPR Design             Feng Zhang lab, Massachusetts Institute of Technology   <http://crispr.mit.edu/>
  CRISPR Design tool        The Broad Institute of Harvard and MIT                  <http://www.broadinstitute.org/mpg/crispr_design/>
  CRISPR/Cas9 gRNA finder   Jack Lin lab, University of Colorado                    <http://spot.colorado.edu/~slin/cas9.html>
  CRISPRfinder              Christine Pourcel lab, Université Paris-Sud 11          <http://crispr.u-psud.fr/Server/>
  E-CRISP                   Boutros lab, DKFZ German Cancer Research Center         <http://www.e-crisp.org/E-CRISP/>
  ZiFiT                     Keith Joung lab, Harvard University                     <http://zifit.partners.org/ZiFiT>
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